XML 25 R15.htm IDEA: XBRL DOCUMENT v3.23.2
Related-Party Transactions
 6 Months Ended
Jun. 30, 2023
Related Party Transactions [Abstract]  
Related-Party Transactions Related-Party Transactions
The Company has outstanding licensing and scientific research agreements with Penn, a significant shareholder (Note 5). The Company recognized $0.2 million of research and development expenses for the three months ended June 30, 2022 related to the Penn License Agreement. No expense was recognized for the three months ended June 30, 2023. The Company recognized $0.3 million and $0.4 million of research and development expenses for the six months ended June 30, 2023 and 2022, respectively, related to the Penn License Agreement.
The Company has a collaboration and license agreement with Moderna, a significant shareholder (Note 10). The Company recognized revenue of $3.6 million and $2.7 million for the three months ended June 30, 2023 and 2022, respectively, related to the Moderna License Agreement. The Company recognized revenue of $6.8 million and $3.5 million for the six months ended June 30, 2023 and 2022, respectively, related to the Moderna License Agreement.